The effect of oxygen impurities on the stability and structural properties of vacancy-ordered and -disordered ZrC x.

Theoretical calculations predict several long-range ordered sub-stoichiometric zirconium carbide phases to be stable at low temperature, rather than a random (disordered solution) distribution of vacancies. However, experimental synthesis of vacancy-ordered phases is extremely challenging and not all predicted phases have been experimentally observed. It has been hypothesised that the inevitable oxygen contamination in experimental samples may affect the vacancy ordering. In this work, the stability and structural properties of the vacancy-ordered and vacancy-disordered phases are investigated as a function of oxygen defect concentration using first-principles calculations. The observed trends are explained in terms of changes to the local bonding in the presence of varying amounts of oxygen and vacancies. It is found that the relative stability of the ordered phases (compared to the disordered phase at the same composition) decreases as oxygen concentration increases, and some vacancy-ordered phases are destabilised by the level of oxygen impurities found in experimental samples. This suggests that oxygen contamination is a contributing factor to the challenge of synthesising ordered zirconium carbides, and gives insight that may assist fabrication in the future. The volume of all ZrC x (x ≤ 1) phases was found to decrease with increasing oxygen concentration, which can be attributed to the different ionocovalent nature of the C-Zr and O-Zr bonds. The volume of the vacancy-ordered phases within the expected oxygen solubility limit is greater than the disordered phase of the same composition, which is explained in terms of the relative bond strengths surrounding different vacancy distributions.

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

Signaling through JAK1 and/or JAK2 is common among tumor and nontumor cells within peripheral T-cell lymphoma (PTCL). No oral therapies are approved for PTCL, and better treatments for relapsed/refractory disease are urgently needed. We conducted a phase 2 study of the JAK1/2 inhibitor ruxolitinib for patients with relapsed/refractory PTCL (n = 45) or mycosis fungoides (MF) (n = 7). Patients enrolled onto 1 of 3 biomarker-defined cohorts: (1) activating JAK and/or STAT mutations, (2) ≥30% pSTAT3 expression among tumor cells by immunohistochemistry, or (3) neither or insufficient tissue to assess. Patients received ruxolitinib 20 mg PO twice daily until progression and were assessed for response after cycles 2 and 5 and every 3 cycles thereafter. The primary endpoint was clinical benefit rate (CBR), defined as the combination of complete response, partial response (PR), and stable disease lasting at least 6 months. Only 1 of 7 patients with MF had CBR (ongoing PR > 18 months). CBR among the PTCL cases (n = 45) in cohorts 1, 2, and 3 were 53%, 45%, and 13% (cohorts 1 & 2 vs 3, P = .02), respectively. Eight patients had CBR > 12 months (5 ongoing), including 4 of 5 patients with T-cell large granular lymphocytic leukemia. In an exploratory analysis using multiplex immunofluorescence, expression of phosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, in <25% of tumor cells was associated with response to ruxolitinib (P = .05). Our findings indicate that ruxolitinib is active across various PTCL subtypes and support a precision therapy approach to JAK/STAT inhibition in patients with PTCL. This trial was registered at www.clincialtrials.gov as #NCT02974647.

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2, days 1 and 8), given on 21-day cycles. The primary end point was complete response (CR) following up to four cycles of pembro-GVD. Patients who achieved CR by labeled fluorodeoxyglucose-positron emission tomography (Deauville ≤ 3) after two or four cycles proceeded to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). HDT/AHCT was carried out according to institutional standards, and brentuximab vedotin maintenance was allowed following HDT/AHCT. RESULTS: Of 39 patients enrolled, 41% had primary ref disease and 38% relapsed within 1 year of frontline treatment. 31 patients received two cycles of pembro-GVD, and eight received four cycles. Most adverse events were grade 1 or two, whereas few were grade 3 and included transaminitis (n = 4), neutropenia (n = 4), mucositis (n = 2), thyroiditis (n = 1), and rash (n = 1). Of 38 evaluable patients, overall and CR rates after pembro-GVD were 100% and 95%, respectively. Thirty-six (95%) patients proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance. All 36 transplanted patients are in remission at a median post-transplant follow-up of 13.5 months (range: 2.66-27.06 months). CONCLUSION: Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.

Stability and structural properties of vacancy-ordered and -disordered ZrC x.

Vacancy-ordered superstructural phases of zirconium carbide have been intermittently observed at low temperatures for over 50 years. However, little is known about these ordered phases as they have proven to be challenging to fabricate experimentally, although theoretical predictions suggest that they should be significantly more stable than the more-observed vacancy-disordered solid solution ZrC x (x ≤ 1) phase at low temperatures. The stability and structural properties of the vacancy-ordered and vacancy-disordered phases are investigated using first-principles calculations. The stability of the ordered superstructural phases is related to the driving force from the relative instability of certain vacancy configurations, which are preferred or avoided in ordered structures. The trend of the vacancy ordering and the underlying mechanisms of the relative instability are explained in terms of the geometry of the crystal structures and the electronic charge distribution and atomic bonding features.

Influence and Sensitivity of Temperature and Microstructure on the Fluctuation of Creep Properties in Ni-Base Superalloy.

In this work, the sensitivity zone of microstructure and temperature for precipitation-strengthened nickel-based superalloys, used for turbine applications in aero-engines, has been firstly established. Heat treatment experiments with different solution temperatures were carried out. The microstructure evolution and creep residual strain sensitivity, low cycle fatigue properties, and tensile properties are analyzed, and the essential reason for the fluctuation of the mechanical properties of nickel-based superalloys was revealed. The main results obtained are as follows: following subsolvus solution heat treatment with a temperature of 1020 °C, samples have a high primary γ'I phase content, which is beneficial to low creep residual strain. Above the supersolvus solution temperature of 1040 °C, the creep residual strain value and low cycle fatigue performance fluctuate significantly. The essential reason for the dramatic fluctuation of performance is the presence of γ' phases in different sizes and quantities, especially following the solution heat treatment in the temperature-sensitive zone of the γ'I phase, which is likely to cause huge fluctuations in the microstructure of tertiary γ'III phases. A zone of particular sensitivity in terms of temperature and microstructure for the γ'I phase is proposed. The range of suitable solution temperatures are discussed. In order to maintain stable mechanical properties without large fluctuations, the influence of the sensitivity within this temperature and microstructure zone on the γ' phase should be considered.